[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053899":3},{"organization":4,"outcomesModule":7,"designInfo":37,"detailedDescription":36,"studyPopulation":36,"armGroups":44,"interventions":50,"overallOfficials":56,"centralContacts":60,"locations":67,"responsibleParty":124,"collaborators":36,"id":126,"slug":127,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":128,"sex":134,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":36,"studyType":140,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":70,"whyStopped":36,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},{"fullName":5,"class":6},"Centre Jean Perrin","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":36},[9],{"measure":10,"description":11,"timeFrame":12},"cDNA detection and objective response 3 months after the end of chemoradiotherapy","The detection or non detection of cDNA after treatment will be compared with the objective response (complete response versus progression\u002Fstability\u002Fpartial response)","3 months after chemoradiotherapy",[14,17,21,24,28,32],{"measure":15,"description":11,"timeFrame":16},"cDNA detection and objective response one month after the end of chemoradiotherapy","1 month after the end of chemoradiotherapy",{"measure":18,"description":19,"timeFrame":20},"Overall survival","The overall survival is defined as the time between the date of inclusion and the date of death from any cause.","At the end of the main study (27 months after the end of treatment)",{"measure":22,"description":23,"timeFrame":20},"Progression-free survival","The progression-free survival is defined as the time between the date of inclusion and the date of the first progression of the disease (clinical or radiological) or death from any cause.",{"measure":25,"description":26,"timeFrame":27},"cDNA kinetic","cDNA detection at 1 and 3 months after the end of chemoradiotherapy","1- and 3-month after the end of chemoradiotherapy",{"measure":29,"description":30,"timeFrame":31},"Concordance of mutational profiles and HPV-HR genotypes between primary tumor, ctDNA at diagnosis and ctDNA","This will be evaluated according to the mutational profile determined by NGS at each timepoint","1- and 3-months after the end of chemoradiotherapy",{"measure":33,"description":34,"timeFrame":35},"Determining the most frequent mutations.","That will be evaluated by analysing the results of NGS (among the 194 genes in our panel)","3-months after the end of chemoradiotherapy",null,{"allocation":38,"interventionModel":39,"interventionModelDescription":40,"primaryPurpose":41,"observationalModel":36,"timePerspective":36,"maskingInfo":42},"NA","SINGLE_GROUP","All the patients will have a blood sample collected one month after the end of chemoradiotherapy and another at three months (excepted if already done in the main study NeckTAR, e.g., if patient have residual disease and an indication for salvage adenectomy).","SCREENING",{"masking":43,"maskingDescription":36,"whoMasked":36},"NONE",[45],{"label":46,"type":47,"description":36,"interventionNames":48},"cDNA detection","EXPERIMENTAL",[49],"Biological: blood sampling",[51],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":36},"BIOLOGICAL","blood sampling","The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy",[46],[57],{"name":58,"affiliation":5,"role":59},"Maureen BERNADACH Coordinator, MD","STUDY_DIRECTOR",[61],{"name":62,"role":63,"phone":64,"phoneExt":65,"email":66},"Angeline GINZAC COUVÉ Project manager, PhD","CONTACT","0463663337","+33","angeline.ginzac@clermont.unicancer.fr",[68,87,102,113],{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"CH Henri Mondor Aurillac","RECRUITING","Aurillac","CANTAL","15000","France","FR",{"type":77,"coordinates":78},"Point",[79,80],2.43983,44.92539,{"lat":80,"lon":79},[83],{"name":84,"role":63,"phone":85,"phoneExt":36,"email":86},"Daniela BURLACU, Dr","0471465613","d.burlacu@ch-aurillac.fr",{"facility":88,"status":70,"city":89,"state":90,"zip":91,"country":74,"countryCode":75,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Centre Jean PERRIN","Clermont-Ferrand","Puy-de-Dôme","63011",{"type":77,"coordinates":93},[94,95],3.08682,45.77969,{"lat":95,"lon":94},[98,100],{"name":99,"role":63,"phone":64,"phoneExt":65,"email":66},"Angeline GINZAC Project manager, PhD",{"name":58,"role":101,"phone":36,"phoneExt":36,"email":36},"PRINCIPAL_INVESTIGATOR",{"facility":103,"status":70,"city":104,"state":36,"zip":36,"country":74,"countryCode":75,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Hôpital de la Croix-Rousse","Lyon",{"type":77,"coordinates":106},[107,108],4.84789,45.74906,{"lat":108,"lon":107},[111],{"name":112,"role":101,"phone":36,"phoneExt":36,"email":36},"Philippe CÉRUSE, Pr",{"facility":114,"status":70,"city":115,"state":36,"zip":36,"country":74,"countryCode":75,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"CHU de Saint-Étienne","Saint-Etienne",{"type":77,"coordinates":117},[118,119],4.39,45.43389,{"lat":119,"lon":118},[122],{"name":123,"role":101,"phone":36,"phoneExt":36,"email":36},"Yann LELONGE, Dr",{"type":125,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100053899","cdna-and-residual-disease-after-chemoradiotherapy-for-locally-advanced-head-and-neck-squamous-cell-carcinomas-100053899",false,"NCT07178847","cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas","Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma","NeckTAR-IN","Selection Criteria:\n\n* Patient included in NeckTAR study\n* Written informed consent signed for NeckTAR-IN study\n* Affiliation to the French social security system","ALL","18 Years","80 Years",{"count":138,"type":139},59,"ESTIMATED","INTERVENTIONAL",[38],"The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.\n\nThe main question it aims to answer is :\n\n\\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).\n\nParticipants will :\n\n* be included in the main study (Neck-TAR)\n* have a blood sample 1 and 3-month after the end of treatment",[144],"Locally Advanced Head and Neck Carcinoma",[146,147],"circulating DNA","residual disease","2026-07-10",{"date":150,"type":151},"2026-07-13","ACTUAL",{"date":153,"type":151},"2025-10-13",{"date":155,"type":139},"2031-07",{"name":5,"class":6},4]